ECONOMIC MODEL TO EXAMINE THE COST BENEFIT ASSOCIATED WITH RESOLUTION OR IMPROVEMENT OF CARCINOID SYNDROME SYMPTOMS FOLLOWING TREATMENT WITH ABOVE-STANDARD DOSE OF OCTREOTIDE-LAR IN PATIENTS WITH NEUROENDOCRINE TUMORS BASED ON DATA FROM A R ...
Abstract
Authors
L. Huynh T. Totev F. Vekeman M. Neary M.S. Duh M. Kulke A. Benson